openPR Logo
Press release

F-star Therapeutics Ltd "FS118 market size expected to increase many folds by 2032, report DelveInsight

03-21-2024 08:19 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

F-star Therapeutics Ltd "FS118 market size expected to increase

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on FS118 (F-star Therapeutics Ltd) providing insights into the drug market landscape and market forecast of FS118 upto 2032. The report, titled "FS118 Market Size, Forecast, and Emerging Insight - 2035" is now available for review and analysis.
Are you interested in finding out the projected market size of FS118 in 2032? FS118 Market Forecast
https://www.delveinsight.com/report-store/fs118-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The FS118 Market Report offers projected sales forecasts for FS118 for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
F-star Therapeutics Ltd's FS118 is serving as a beacon of hope for the patients suffering from the LAG-3 Next-generation Immunotherapies.
What is a FS118 Prescribed for?
FS118 showed strong binding to both LAG-3 and PD-L1 simultaneously, exhibiting high affinity and efficacy similar to or surpassing that of the individual components in blocking immune suppression and boosting T-cell activity. In mouse models with syngeneic tumors, mLAG-3/PD-L1 mAb2 notably inhibited tumor growth.

The report extensively covers the details and developments related to FS118, capturing important highlights on developmental pipeline, regulatory status and special designations of FS118, route of administration, safety and efficacy details.

FS118 Market Assessment
This report provides a detailed market assessment of FS118 for LAG-3 Next-generation Immunotherapies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

FS118 Clinical Assessment
The report provides the clinical trials information of FS118 for LAG-3 Next-generation Immunotherapies covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against FS118? FS118 Drugs Insights
https://www.delveinsight.com/report-store/fs118-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

FS118 Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the FS118.

FS118 Market Size in the US
A dedicated section of the report focuses on the expected market size of FS118 for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of FS118:

• The report contains forecasted sales of FS118 for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for LAG-3 Next-generation Immunotherapies.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for FS118 in LAG-3 Next-generation Immunotherapies.
Stay ahead in competition by leveraging insights on FS118 market Report: Download FS118 Market Report
https://www.delveinsight.com/sample-request/fs118-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy FS118 Market Report:
• The report provides future market assessments for FS118 for LAG-3 Next-generation Immunotherapies in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading FS118 for LAG-3 Next-generation Immunotherapies forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FS118
• Discover the competitive landscape of FS118 through 7MM
• Get a Thorough Analysis of the FS118 Development pipeline, Safety & Efficacy of the FS118, and ROA
• Thorough FS118 market forecast will help understand how drug is competing with other emerging FS118
• Get analysis of the FS118 clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Top Services Offered By DelveInsight:

Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Latest Reports Offered By DelveInsight:

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release F-star Therapeutics Ltd "FS118 market size expected to increase many folds by 2032, report DelveInsight here

News-ID: 3439812 • Views:

More Releases from DelveInsight Business Research

Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining the Future of Treatment, analyses DelveInsight
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies Advancing Next-Generation ILD Therapies, analyses DelveInsight
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by 2032, estimates DelveInsight
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry. Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Future of Treatment, analyses DelveInsight
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline. Stay informed with

All 5 Releases


More Releases for FS118

Lag-3-next Generation Immunotherapy Market to Witness Growth by 2032, Estimates …
DelveInsight's "Lag-3-next Generation Immunotherapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lag-3-next Generation Immunotherapy, historical and forecasted epidemiology as well as the Lag-3-next Generation Immunotherapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Lag-3-next Generation Immunotherapy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
Lag-3-next Generation Immunotherapy Market to Witness Growth by 2032, Estimates …
DelveInsight's "Lag-3-next Generation Immunotherapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lag-3-next Generation Immunotherapy, historical and forecasted epidemiology as well as the Lag-3-next Generation Immunotherapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Lag-3-next Generation Immunotherapy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
Lag-3-next Generation Immunotherapy Market to Witness Growth by 2032, Estimates …
DelveInsight's "Lag-3-next Generation Immunotherapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lag-3-next Generation Immunotherapy, historical and forecasted epidemiology as well as the Lag-3-next Generation Immunotherapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Lag-3-next Generation Immunotherapy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted
The LAG-3-Next Generation Immunotherapy Market Size is projected to reach ~USD 6 …
DelveInsight's LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, Germany, the United Kingdom, Spain, and Italy) and Japan]. To know more about the LAG-3-Next Generation
Global CD233 Antibody Market Clinical Trials Intelligence 2028
Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1
Lymphocyte Activation Gene 3 Protein Market- Size, Share, Outlook, and Forecast …
Lymphocyte-activation gene 3, also known as LAG-3, is a protein that is has diverse biological effects on the functioning of T cells. This protein was first discovered in 1990. LAG-3 is an immune checkpoint receptor, and is thus used as the target of various drug development programs. Increasing prevalence of chronic diseases such as cancer and autoimmune diseases such as AIDS are expected to increase the demand for treatment measures. This